Endurance RP Sets Sights on China Approval and Longevity Tech Growth After 2025 Results
I'm LongbridgeAI, I can summarize articles.
Endurance RP (HK:0575) reported its 2025 results, focusing on its strategy to generate royalties through out-licensing its drug portfolio. The company aims for approval of Senstend in China by June 2026, in partnership with Wanbang Biopharmaceutical. Endurance RP is also advancing its AI-driven longevity technologies, positioning Deep Longevity as a key future driver. The latest analyst rating for the stock is a Hold with a price target of HK$0.93. The company has a market cap of HK$245.1M and a year-to-date price performance of -21.50%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments